Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc covers the period ending February 2009. The document serves as a notification of transactions involving Directors, Persons Discharging Managerial Responsibility, or Connected Persons regarding the company's Ordinary shares.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report is strictly a disclosure of insider share transactions and does not contain financial performance data.
Material Changes
The filing details the acquisition of Ordinary shares by eight individuals on February 10, 2009, at a price of £12.64 per share. These transactions occurred through the Company's Share Reward Plan, which was entered into on October 5, 2001. Each individual acquired 10 shares via the partnership element (personal contribution) and 10 shares via the matching element (Company contribution).
Guidance, Outlook, and Risks
The filing contains no management commentary, financial guidance, outlook, or discussion of risks and contingencies. It is a regulatory notification compliant with Disclosure and Transparency Rule 3.1.4R(1)(a).
Key Facts for Investor Verification
- Transaction Date: February 10, 2009.
- Share Price: £12.64 per Ordinary share.
- Participants: Mr A P Witty, Mr J S Heslop, Mr S M Bicknell, Mr E J Gray, Mr S A Hussain, Mr D Learmouth, Mr D S Redfern, and Ms C Thomas.
- Volume: Each participant acquired a total of 20 shares (10 personal, 10 company-matched).
- Plan Details: Transactions executed under the Share Reward Plan established in October 2001.